Mitokinin Presents at 3rd Annual Sachs Neuroscience Investor Forum
January 12, 2020
Mitokinin joined 300 delegates from the biopharma and venture industries and 35 peer companies at the 3rd annual Sachs Neuroscience Investor Forum, held in San Francisco 1/12/2020. Mitokinin CEO Daniel de Roulet led a presentation on the Company’s history and strategy, while CSO Nicholas Hertz, PhD, joined a panel of scientific leaders to discuss emerging therapeutic approaches in the neurodegenerative disease space.
“It was a pleasure for us to share our story with our peers and the VCs at the conference today,” said Mr. de Roulet. “It was a great way to kick off the JPMorgan week. We commend Sachs Associates for putting on a well-run show.”
Mitokinin is late-preclinical stage biotechnology company developing PINK1-targeted therapeutics for Parkinson’s disease. By selectively amplifying active-form PINK1 activity, Mitokinin believes it can address the cellular pathologies underlying Parkinson’s disease and ultimately slow or halt the progression of the disease. Learn more at www.mitokinin.com.